Close

Galena Biopharma (GALE): Primary Analysis Supports GALE-301's Positive Effect on Disease-Free Survival - FBR

June 7, 2016 10:02 AM EDT Send to a Friend
FBR Capital analyst, Vernon Bernardino, noted that in a poster presentation yesterday at the American Society of Clinical Oncology (ASCO) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login